236 related articles for article (PubMed ID: 36791846)
1. Nirmatrelvir exerts distinct antiviral potency against different human coronaviruses.
Li J; Wang Y; Solanki K; Atre R; Lavrijsen M; Pan Q; Baig MS; Li P
Antiviral Res; 2023 Mar; 211():105555. PubMed ID: 36791846
[TBL] [Abstract][Full Text] [Related]
2. Immunosuppressants exert differential effects on pan-coronavirus infection and distinct combinatory antiviral activity with molnupiravir and nirmatrelvir.
Wang Y; Li P; Lavrijsen M; Rottier RJ; den Hoed CM; Bruno MJ; Kamar N; Peppelenbosch MP; de Vries AC; Pan Q
United European Gastroenterol J; 2023 Jun; 11(5):431-447. PubMed ID: 37226653
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of
Tong X; Keung W; Arnold LD; Stevens LJ; Pruijssers AJ; Kook S; Lopatin U; Denison M; Kwong AD
Antimicrob Agents Chemother; 2023 Nov; 67(11):e0084023. PubMed ID: 37800975
[TBL] [Abstract][Full Text] [Related]
4. Immunodetection assays for the quantification of seasonal common cold coronaviruses OC43, NL63, or 229E infection confirm nirmatrelvir as broad coronavirus inhibitor.
Weil T; Lawrenz J; Seidel A; Münch J; Müller JA
Antiviral Res; 2022 Jul; 203():105343. PubMed ID: 35598779
[TBL] [Abstract][Full Text] [Related]
5. Recapitulating infection, thermal sensitivity and antiviral treatment of seasonal coronaviruses in human airway organoids.
Li P; Wang Y; Lamers MM; Lavrijsen M; Iriondo C; de Vries AC; Rottier RJ; Peppelenbosch MP; Haagmans BL; Pan Q
EBioMedicine; 2022 Jul; 81():104132. PubMed ID: 35779493
[TBL] [Abstract][Full Text] [Related]
6. Viral polymerase binding and broad-spectrum antiviral activity of molnupiravir against human seasonal coronaviruses.
Wang Y; Li P; Solanki K; Li Y; Ma Z; Peppelenbosch MP; Baig MS; Pan Q
Virology; 2021 Dec; 564():33-38. PubMed ID: 34619630
[TBL] [Abstract][Full Text] [Related]
7. A viral RNA-dependent RNA polymerase inhibitor VV116 broadly inhibits human coronaviruses and has synergistic potency with 3CLpro inhibitor nirmatrelvir.
Zhang Y; Sun Y; Xie Y; Shang W; Wang Z; Jiang H; Shen J; Xiao G; Zhang L
Signal Transduct Target Ther; 2023 Sep; 8(1):360. PubMed ID: 37735468
[TBL] [Abstract][Full Text] [Related]
8. Differing pan-coronavirus antiviral potency of boceprevir and GC376 in vitro despite discordant molecular docking predictions.
Wang Y; Li P; Lavrijsen M; Li Y; Ma Z; Peppelenbosch MP; Baig MS; Pan Q
Arch Virol; 2022 Apr; 167(4):1125-1130. PubMed ID: 35171357
[TBL] [Abstract][Full Text] [Related]
9. Investigating theobromine as a potential anti-human coronaviral agent.
Li J; Wang Y; Rajpoot S; Lavrijsen M; Pan Q; Li P; Baig MS
Microbiol Immunol; 2023 Sep; 67(9):404-412. PubMed ID: 37415325
[TBL] [Abstract][Full Text] [Related]
10. Genetic Surveillance of SARS-CoV-2 M
Lee JT; Yang Q; Gribenko A; Perrin BS; Zhu Y; Cardin R; Liberator PA; Anderson AS; Hao L
mBio; 2022 Aug; 13(4):e0086922. PubMed ID: 35862764
[TBL] [Abstract][Full Text] [Related]
11. The efficacy of Paxlovid against COVID-19 is the result of the tight molecular docking between M
Dawood AA
Adv Med Sci; 2023 Mar; 68(1):1-9. PubMed ID: 36368287
[TBL] [Abstract][Full Text] [Related]
12. Brilacidin, a COVID-19 drug candidate, demonstrates broad-spectrum antiviral activity against human coronaviruses OC43, 229E, and NL63 through targeting both the virus and the host cell.
Hu Y; Jo H; DeGrado WF; Wang J
J Med Virol; 2022 May; 94(5):2188-2200. PubMed ID: 35080027
[TBL] [Abstract][Full Text] [Related]
13. Severe Acute Respiratory Syndrome Coronavirus 2 Vaccination Boosts Neutralizing Activity Against Seasonal Human Coronaviruses.
Lawrenz J; Xie Q; Zech F; Weil T; Seidel A; Krnavek D; van der Hoek L; Münch J; Müller JA; Kirchhoff F
Clin Infect Dis; 2022 Aug; 75(1):e653-e661. PubMed ID: 35079775
[TBL] [Abstract][Full Text] [Related]
14. Repurposing dyphylline as a pan-coronavirus antiviral therapy.
Wang Y; Rajpoot S; Li P; Lavrijsen M; Ma Z; Hirani N; Saqib U; Pan Q; Baig MS
Future Med Chem; 2022 May; 14(10):685-699. PubMed ID: 35387498
[No Abstract] [Full Text] [Related]
15. More tools for our toolkit: The application of HEL-299 cells and dsRNA-nanoparticles to study human coronaviruses in vitro.
Semple SL; Alkie TN; Jenik K; Warner BM; Tailor N; Kobasa D; DeWitte-Orr SJ
Virus Res; 2022 Nov; 321():198925. PubMed ID: 36115551
[TBL] [Abstract][Full Text] [Related]
16. Human coronaviruses 229E and OC43 replicate and induce distinct antiviral responses in differentiated primary human bronchial epithelial cells.
Loo SL; Wark PAB; Esneau C; Nichol KS; Hsu AC; Bartlett NW
Am J Physiol Lung Cell Mol Physiol; 2020 Dec; 319(6):L926-L931. PubMed ID: 32903043
[TBL] [Abstract][Full Text] [Related]
17. Interactions of the Anti-SARS-CoV-2 Agents Molnupiravir and Nirmatrelvir/Paxlovid with Human Drug Transporters.
Bakos É; Temesszentandrási-Ambrus C; Özvegy-Laczka C; Gáborik Z; Sarkadi B; Telbisz Á
Int J Mol Sci; 2023 Jul; 24(14):. PubMed ID: 37510996
[TBL] [Abstract][Full Text] [Related]
18. Molnupiravir and Nirmatrelvir-Ritonavir: Oral Coronavirus Disease 2019 Antiviral Drugs.
Saravolatz LD; Depcinski S; Sharma M
Clin Infect Dis; 2023 Jan; 76(1):165-171. PubMed ID: 35245942
[TBL] [Abstract][Full Text] [Related]
19. Cytopathic Effect Assay and Plaque Assay to Evaluate
Hu Y; Ma C; Wang J
Bio Protoc; 2022 Feb; 12(3):e4314. PubMed ID: 35284599
[TBL] [Abstract][Full Text] [Related]
20. Combinations of Host- and Virus-Targeting Antiviral Drugs Confer Synergistic Suppression of SARS-CoV-2.
Wagoner J; Herring S; Hsiang TY; Ianevski A; Biering SB; Xu S; Hoffmann M; Pöhlmann S; Gale M; Aittokallio T; Schiffer JT; White JM; Polyak SJ
Microbiol Spectr; 2022 Oct; 10(5):e0333122. PubMed ID: 36190406
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
